Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated May 19, 2010, reports on a significant legal development involving its US affiliate, Novartis Pharmaceuticals Corporation (NPC). The filing addresses a jury verdict in the class-action lawsuit Velez v. NPC, which was filed in 2004 and certified in 2007. The case concerned allegations of past discrimination in the sales force regarding pay, promotion, and pregnancy during the period of 2002 to 2007.
Key Financial Metrics and Litigation Impact
The filing does not provide current period revenue, profit, cash flow, or margin data. However, it details specific financial liabilities resulting from the litigation verdict:
- Compensatory Damages: USD 3.3 million awarded to testifying witnesses.
- Punitive Damages: USD 250 million awarded against the Novartis US affiliate.
- Historical Context: The "About Novartis" section notes that in 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, with approximately USD 7.5 billion invested in R&D.
Material Changes and Management Commentary
Management strongly disputes the jury's findings, stating that the company has maintained high standards for diversity and inclusion for over ten years. Key points from management include:
- Dispute of Claims: NPC asserts that its policies and programs actively support the advancement of women and foster an inclusive environment.
- Recognition: NPC has been recognized for ten consecutive years by Working Mother magazine as a top 100 company for working mothers and has been named to the DiversityInc Top 50 list since 2005.
- Employee Support: The company supports 16 Employee Resource Groups, including "Women in Leadership," and offers comprehensive benefits such as up to 26 weeks of paid short-term disability leave for pregnancy and 12 weeks of unpaid family career leave.
- Procedural Context: Management noted that several class members voluntarily testified on the company's behalf but were unable to opt-out of the lawsuit due to the class certification structure.
- Litigation Uncertainty: The inherent unpredictability of the litigation process and the possibility that actual results may vary materially from expectations.
- Financial Contingency: The potential financial impact of the USD 250 million punitive damages award if the verdict stands or is upheld on appeal.
- Verify the total potential financial exposure, specifically the USD 250 million punitive damages and USD 3.3 million compensatory damages.
- Monitor the status of any appeal filed by Novartis Pharmaceuticals Corporation against the jury verdict.
- Review the company's Form 20-F for a comprehensive list of risks and factors that could affect the outcome of the litigation.
- Confirm whether the company has accrued these damages in its financial statements or if they are disclosed as contingent liabilities.
Risks, Contingencies, and Outlook
The filing contains forward-looking statements regarding the potential outcome of any appeal. Management explicitly states there can be no guarantee of success in an appeal. Risks include: